From the Department of Body and Interventional Imaging (M.B., P.S.) and UMR INSERM 965 (M.B., P.S.), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Department of Body and Interventional Imaging (M.B., P.S.) and UMR INSERM 965 (M.B., P.S.), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Department of Radiology, Body MR Imaging and Translational And Molecular Imaging Institute, Mount Sinai Medical Center, New York, NY (B.T.); Department of Diagnostic and Interventional Radiology, Hôpital Le Bocage, Dijon, France (B.G.); Department of Radiology, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, Sutton, England (D.M.K.); Department of Radiology, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France (A.L.); Department of Radiology, University of Verona, Verona, Italy (R.M.); Department of Radiology, Hôpital Beaujon, Clichy, France (V.V.); Department of Radiology, Hôpital Robert Debré, Reims, France (C.H.); Department of Radiology, Gifu University Hospital, Gifu, Japan (M.K.); and Université Paris-Diderot, Sorbonne Paris Cité, Paris, France (P.S.).
Radiology. 2015 Jan;274(1):45-63. doi: 10.1148/radiol.14130778.
Advances in image quality over the past few years, mainly due to refinements in hardware and coil systems, have made diffusion-weighted ( DW diffusion weighted ) magnetic resonance (MR) imaging a promising technique for the detection and characterization of pancreatic conditions. DW diffusion weighted MR imaging can be routinely implemented in clinical protocols, as it can be performed relatively quickly, does not require administration of gadolinium-based contrast agents, and enables qualitative and quantitative assessment of tissue diffusivity (diffusion coefficients). In this review, acquisition parameters, postprocessing, and quantification methods applied to pancreatic DW diffusion weighted MR imaging will be discussed. The current common clinical uses of DW diffusion weighted MR imaging (ie, pancreatic lesion detection and characterization) and the less-common applications of DW diffusion weighted MR imaging used for the diagnosis of pancreatic parenchymal diseases will be reviewed. Also, the limitations of the technique, mainly image quality and reproducibility of diffusion parameters, as well as future directions for pancreatic DW diffusion weighted MR imaging will be discussed. The utility of apparent diffusion coefficient ( ADC apparent diffusion coefficient ) measurement for the characterization of pancreatic lesions is now well accepted but there are a number of limitations. Future well-designed, multicenter studies are needed to better determine the most appropriate use of ADC apparent diffusion coefficient in the area of pancreatic disease.
在过去几年中,图像质量的进步主要归因于硬件和线圈系统的改进,使扩散加权(DW 扩散加权)磁共振成像(MR)成为检测和描述胰腺疾病的一种很有前途的技术。DW 扩散加权 MR 成像可以常规地应用于临床方案,因为它可以相对快速地进行,不需要施用钆基造影剂,并能够对组织扩散率(扩散系数)进行定性和定量评估。在这篇综述中,将讨论应用于胰腺 DW 扩散加权 MR 成像的采集参数、后处理和定量方法。将回顾 DW 扩散加权 MR 成像的当前常见临床用途(即胰腺病变的检测和特征描述)和不太常见的用于诊断胰腺实质疾病的 DW 扩散加权 MR 成像应用。还将讨论该技术的局限性,主要是图像质量和扩散参数的可重复性,以及胰腺 DW 扩散加权 MR 成像的未来方向。目前已经很好地接受了表观扩散系数(ADC 表观扩散系数)测量在胰腺病变特征描述中的作用,但仍存在一些局限性。需要进行未来的精心设计的多中心研究,以更好地确定 ADC 表观扩散系数在胰腺疾病领域的最适当用途。